Identification
- Summary
Sulpiride is a selective D2 dopamine receptor antagonist indicated to treat chronic and acute schizophrenia.
- Generic Name
- Sulpiride
- DrugBank Accession Number
- DB00391
- Background
Sulpiride first appeared in published literature in 1967.1 Clinical studies show a greater effect on treating the negative symptoms of schizophrenia rather than positive symptoms at low doses, though the effects are more equal at higher doses.7
Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.11
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Sulpiride (DB00391)
- Weight
- Average: 341.426
Monoisotopic: 341.140926929 - Chemical Formula
- C15H23N3O4S
- Synonyms
- (±)-sulpiride
- 5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide
- N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide
- N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide
- Sulpirid
- Sulpirida
- Sulpiride
- Sulpiridum
- Sulpyrid
Pharmacology
- Indication
Sulpiride is indicated for the treatment of acute and chronic schizophrenia.10
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Sulpiride is a substituted benzamide derivative and a selective dopamine D2 antagonist indicated to treat acute and chronic schizophrenia.6,7,8,10 It has a short duration of action as it is given twice daily, and a wide therapeutic window as patients have survived single doses as high as 16g.10 Patients should be counselled regarding increased motor agitation, extrapyramidal reactions, and neuroleptic malignant syndrome.10
- Mechanism of action
Sulpiride is a selective dopamine D2 and D3 receptor antagonist.6,7,8 In silico studies show that sulpiride may interact with the Asp-119 and Phe-417 amino acid residues of these receptors.8 It is estimated that D2 receptors should be 65-80% occupied for optimal treatment and minimal adverse effects.9
Target Actions Organism ADopamine D2 receptor antagonistHumans UDopamine D3 receptor antagonistHumans UCarbonic anhydrase 2 inhibitorHumans UCarbonic anhydrase 3 inhibitorHumans UDopamine D4 receptor antagonistHumans - Absorption
Sulpiride has an oral bioavailability of 27 ± 9%.4 A 100-108 mg dose of sulpiride reaches a Cmax of 232-403 ng/mL, with a Tmax of 8.3 h.2 In another study, the AUC of a 100mg oral dose of sulpiride is 1156 ± 522 h*ng/mL and for an intravenous dose is 3981 ± 813 h*ng/mL.4
- Volume of distribution
The average volume of distribution of sulpiride is 2.72 ± 0.66 L/kg.4
- Protein binding
Sulpiride is approximately 40% protein bound in plasma, particularly to albumin.3
- Metabolism
95% of a dose of sulpiride is not metabolized.2
- Route of elimination
An intravenous dose of sulpiride is 70 ± 9% eliminated in the urine within 36 hours, while an oral dose is 27 ± 9% eliminated in urine.4 In both cases, the dose is recovered as the unchanged parent compound.4
- Half-life
Reports of the half life of sulpiride have only been performed with small numbers of subjects.2,4 Therefore, the average half life may be 7.15 hours4 to 8.3 hours.2
- Clearance
The total systemic clearance of sulpiride if 415 ± 84 mL/min, while the mean renal clearance was 310 ± 91 mL/min.4
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Patients experiencing an overdose of sulpiride may present with hypotension, sinus tachycardia, arrhythmia, dystonia, CNS depression, hallucinations, vomiting, agitation, dysarthria, salivation, as well as increased muscle tone, hyperreflexia, and extensor plantar reflex.5 Patients should be treated with symptomatic and supportive treatment.5
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Sulpiride is combined with 1,2-Benzodiazepine. Acebutolol Sulpiride may increase the bradycardic activities of Acebutolol. Acenocoumarol The risk or severity of adverse effects can be increased when Sulpiride is combined with Acenocoumarol. Acetazolamide The risk or severity of adverse effects can be increased when Sulpiride is combined with Acetazolamide. Acetophenazine Acetophenazine may increase the antipsychotic activities of Sulpiride. Acetylcholine The risk or severity of adverse effects can be increased when Sulpiride is combined with Acetylcholine. Acetyldigitoxin The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Acetyldigitoxin. Aclidinium Aclidinium may increase the anticholinergic activities of Sulpiride. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Sulpiride. Adenosine The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Adenosine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Avoid alcohol. Alcohol enhances the sedative effects of sulpiride.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Bosnyl / Dogmatil / Dogmatyl / Dolmatil / Eglonyl / Espiride / Meresa / Modal
Categories
- ATC Codes
- N05AL01 — Sulpiride
- Drug Categories
- Acids, Carbocyclic
- Amides
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Antipsychotic Agents
- BCRP/ABCG2 Substrates
- Benzamides and benzamide derivatives
- Benzene Derivatives
- Benzoates
- Central Nervous System Agents
- Central Nervous System Depressants
- Cholinesterase Inhibitors
- Dopamine Agents
- Dopamine Antagonists
- Dopamine D2 Receptor Antagonists
- MATE 1 Substrates
- MATE 2 Substrates
- MATE substrates
- Moderate Risk QTc-Prolonging Agents
- Nervous System
- Neurotoxic agents
- Neurotransmitter Agents
- OCT1 substrates
- OCT2 Substrates
- P-glycoprotein substrates
- Psycholeptics
- Psychotropic Drugs
- QTc Prolonging Agents
- Tranquilizing Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzenesulfonamides
- Direct Parent
- Benzenesulfonamides
- Alternative Parents
- Benzenesulfonyl compounds / Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / Organosulfonamides / N-alkylpyrrolidines / Aminosulfonyl compounds / Trialkylamines / Propargyl-type 1,3-dipolar organic compounds show 5 more
- Substituents
- Alkyl aryl ether / Amine / Aminosulfonyl compound / Anisole / Aromatic heteromonocyclic compound / Azacycle / Benzenesulfonamide / Benzenesulfonyl group / Carboximidic acid / Carboximidic acid derivative show 23 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- sulfonamide, benzamides, N-alkylpyrrolidine (CHEBI:32168)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 7MNE9M8287
- CAS number
- 15676-16-1
- InChI Key
- BGRJTUBHPOOWDU-UHFFFAOYSA-N
- InChI
- InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
- IUPAC Name
- N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide
- SMILES
- CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
References
- General References
- Justin-Besancon L, Thominet M, Laville C, Margarit J: [Chemical consitution and biological properties of sulpiride]. C R Acad Hebd Seances Acad Sci D. 1967 Oct 23;265(17):1253-4. [Article]
- Imondi AR, Alam AS, Brennan JJ, Hagerman LM: Metabolism of sulpiride in man and rhesus monkeys. Arch Int Pharmacodyn Ther. 1978 Mar;232(1):79-91. [Article]
- da Silva Fragoso VM, de Morais Coura CP, Hoppe LY, Soares MA, Silva D, Cortez CM: Binding of Sulpiride to Seric Albumins. Int J Mol Sci. 2016 Jan 4;17(1). pii: ijms17010059. doi: 10.3390/ijms17010059. [Article]
- Wiesel FA, Alfredsson G, Ehrnebo M, Sedvall G: The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol. 1980 May;17(5):385-91. doi: 10.1007/BF00558453. [Article]
- Capel MM, Colbridge MG, Henry JA: Overdose profiles of new antipsychotic agents. Int J Neuropsychopharmacol. 2000 Mar;3(1):51-54. doi: 10.1017/S1461145700001760. [Article]
- Jenner P, Marsden CD: The mode of action of sulpiride as an atypical antidepressant agent. Adv Biochem Psychopharmacol. 1982;32:85-103. [Article]
- Mauri MC, Bravin S, Bitetto A, Rudelli R, Invernizzi G: A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Drug Saf. 1996 May;14(5):288-98. doi: 10.2165/00002018-199614050-00003. [Article]
- Kecel-Gunduz S, Budama-Kilinc Y, Cakir-Koc R, Zorlu T, Bicak B, Kokcu Y, Kaya Z, Ozel AE, Akyuz S: In silico Analysis of Sulpiride, Synthesis, Characterization and In vitro Studies of its Nanoparticle for the Treatment of Schizophrenia. Curr Comput Aided Drug Des. 2020;16(2):104-121. doi: 10.2174/1573409915666190627125643. [Article]
- Moriguchi S, Bies RR, Remington G, Suzuki T, Mamo DC, Watanabe K, Mimura M, Pollock BG, Uchida H: Estimated dopamine D(2) receptor occupancy and remission in schizophrenia: analysis of the CATIE data. J Clin Psychopharmacol. 2013 Oct;33(5):682-5. doi: 10.1097/JCP.0b013e3182979a0a. [Article]
- Electronic Medicines Compendium: Sulpiride 200 mg Tablets Summary of Product Characteristics [Link]
- AIFA: Levobren (sulpiride) solution for injection, tablet, oral solution [Link]
- External Links
- Human Metabolome Database
- HMDB0014535
- KEGG Drug
- D01226
- PubChem Compound
- 5355
- PubChem Substance
- 46504855
- ChemSpider
- 5162
- BindingDB
- 11638
- 10239
- ChEBI
- 32168
- ChEMBL
- CHEMBL26
- Therapeutic Targets Database
- DAP000310
- PharmGKB
- PA164745485
- Guide to Pharmacology
- GtP Drug Page
- Wikipedia
- Sulpiride
- MSDS
- Download (57 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Schizoaffective Disorders / Schizophrenia / Schizophrenia and Disorders With Psychotic Features 1 4 Completed Treatment Schizophrenia 1 4 Unknown Status Prevention Bowel preparation therapy 1 3 Completed Treatment Hot Flashes / Menopausal Syndromes 1 3 Terminated Treatment Anxiety Disorders / Dementia / Depression / Psychosomatic Disorders / Schizophrenia 1 3 Unknown Status Treatment Psychosis Nos/Other 1 Not Available Completed Not Available Healthy Subjects (HS) 1 Not Available Completed Treatment Physiology, Ocular / Regional Blood Flow 1 Not Available Recruiting Basic Science Placebo Effect on Mood Improvement 1 Not Available Unknown Status Not Available Schizophrenia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intramuscular 100 MG/2ML Syrup Oral 150 ML Tablet Oral 50 mg Capsule Oral Capsule Oral 50 mg/1 Solution Oral 25 mg/5mL Capsule Oral 50 mg Tablet Oral Tablet Oral 200 mg/1 Solution Oral 20 mg Capsule, coated Oral 50 mg Solution Oral 0.5 g Solution Oral Solution / drops Oral 25 MG/ML Tablet Oral 25 MG Injection Injection 100 mg/3ml Tablet, film coated Oral Tablet Oral 100 mg Tablet, film coated Oral 50 MG Solution Oral 100 mg/2ml Tablet Oral 200 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 178 dec °C PhysProp logP 0.57 HOEGBERG,T ET AL. 1986 Caco2 permeability -6.16 ADME Research, USCD pKa 9.12 EL TAYAR,N ET AL. (1985) - Predicted Properties
Property Value Source Water Solubility 0.537 mg/mL ALOGPS logP 1.2 ALOGPS logP 0.22 Chemaxon logS -2.8 ALOGPS pKa (Strongest Acidic) 10.24 Chemaxon pKa (Strongest Basic) 8.39 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 101.73 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 88.63 m3·mol-1 Chemaxon Polarizability 36.18 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9946 Blood Brain Barrier + 0.9444 Caco-2 permeable - 0.8957 P-glycoprotein substrate Substrate 0.7319 P-glycoprotein inhibitor I Non-inhibitor 0.857 P-glycoprotein inhibitor II Non-inhibitor 0.8994 Renal organic cation transporter Non-inhibitor 0.7685 CYP450 2C9 substrate Non-substrate 0.7898 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Non-substrate 0.54 CYP450 1A2 substrate Non-inhibitor 0.9046 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.9656 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9409 Ames test Non AMES toxic 0.6229 Carcinogenicity Non-carcinogens 0.7139 Biodegradation Not ready biodegradable 0.8542 Rat acute toxicity 1.8612 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8546 hERG inhibition (predictor II) Inhibitor 0.549
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Potassium channel regulator activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- DRD2
- Uniprot ID
- P14416
- Uniprot Name
- D(2) dopamine receptor
- Molecular Weight
- 50618.91 Da
References
- Cavallotti C, Nuti F, Bruzzone P, Mancone M: Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):412-8. [Article]
- Jaber M, Tison F, Fournier MC, Bloch B: Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary. Brain Res Mol Brain Res. 1994 Apr;23(1-2):14-20. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- G-protein coupled amine receptor activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
- Gene Name
- DRD3
- Uniprot ID
- P35462
- Uniprot Name
- D(3) dopamine receptor
- Molecular Weight
- 44224.335 Da
References
- Lipina TV, Vishnivetskaia GB: [Effect of sulpiride on immobility reflex and pinch-induced catalepsy in CBA/Lac male mice with various social status]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2009 Jul-Aug;59(4):482-7. [Article]
- Collo G, Zanetti S, Missale C, Spano P: Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur J Neurosci. 2008 Oct;28(7):1231-40. doi: 10.1111/j.1460-9568.2008.06423.x. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Zinc ion binding
- Specific Function
- Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
- Gene Name
- CA2
- Uniprot ID
- P00918
- Uniprot Name
- Carbonic anhydrase 2
- Molecular Weight
- 29245.895 Da
References
- Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Zinc ion binding
- Specific Function
- Reversible hydration of carbon dioxide.
- Gene Name
- CA3
- Uniprot ID
- P07451
- Uniprot Name
- Carbonic anhydrase 3
- Molecular Weight
- 29557.215 Da
References
- Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Sh3 domain binding
- Specific Function
- Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
- Gene Name
- DRD4
- Uniprot ID
- P21917
- Uniprot Name
- D(4) dopamine receptor
- Molecular Weight
- 48359.86 Da
References
- Ciszowski K, Szpak D, Wilimowska J: [Toxicity of sulpiride]. Przegl Lek. 2010;67(8):606-9. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Identical protein binding
- Specific Function
- Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
- Gene Name
- BCHE
- Uniprot ID
- P06276
- Uniprot Name
- Cholinesterase
- Molecular Weight
- 68417.575 Da
References
- Vacca C, Maione S, Tozzi A, Marmo E: Benzamides and cholinesterases. Res Commun Chem Pathol Pharmacol. 1987 Feb;55(2):193-201. [Article]
- Dross K: [The relevance of anticholinesterase properties to toxicity and neuromuscular effects of sulpiride (author's transl)]. Arzneimittelforschung. 1977 Feb;27(2):404-6. [Article]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Binder
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- da Silva Fragoso VM, de Morais Coura CP, Hoppe LY, Soares MA, Silva D, Cortez CM: Binding of Sulpiride to Seric Albumins. Int J Mol Sci. 2016 Jan 4;17(1). pii: ijms17010059. doi: 10.3390/ijms17010059. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Secondary active organic cation transmembrane transporter activity
- Specific Function
- Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
- Gene Name
- SLC22A1
- Uniprot ID
- O15245
- Uniprot Name
- Solute carrier family 22 member 1
- Molecular Weight
- 61153.345 Da
References
- Li L, Weng Y, Wang W, Bai M, Lei H, Zhou H, Jiang H: Multiple organic cation transporters contribute to the renal transport of sulpiride. Biopharm Drug Dispos. 2017 Dec;38(9):526-534. doi: 10.1002/bdd.2104. Epub 2017 Nov 20. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Quaternary ammonium group transmembrane transporter activity
- Specific Function
- Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
- Gene Name
- SLC22A2
- Uniprot ID
- O15244
- Uniprot Name
- Solute carrier family 22 member 2
- Molecular Weight
- 62579.99 Da
References
- Li L, Weng Y, Wang W, Bai M, Lei H, Zhou H, Jiang H: Multiple organic cation transporters contribute to the renal transport of sulpiride. Biopharm Drug Dispos. 2017 Dec;38(9):526-534. doi: 10.1002/bdd.2104. Epub 2017 Nov 20. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Monovalent cation:proton antiporter activity
- Specific Function
- Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfat...
- Gene Name
- SLC47A1
- Uniprot ID
- Q96FL8
- Uniprot Name
- Multidrug and toxin extrusion protein 1
- Molecular Weight
- 61921.585 Da
References
- Takano H, Ito S, Zhang X, Ito H, Zhang MR, Suzuki H, Maeda K, Kusuhara H, Suhara T, Sugiyama Y: Possible Role of Organic Cation Transporters in the Distribution of [(11)C]Sulpiride, a Dopamine D2 Receptor Antagonist. J Pharm Sci. 2017 Sep;106(9):2558-2565. doi: 10.1016/j.xphs.2017.05.006. Epub 2017 May 10. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Drug transmembrane transporter activity
- Specific Function
- Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide, metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acy...
- Gene Name
- SLC47A2
- Uniprot ID
- Q86VL8
- Uniprot Name
- Multidrug and toxin extrusion protein 2
- Molecular Weight
- 65083.915 Da
References
- Takano H, Ito S, Zhang X, Ito H, Zhang MR, Suzuki H, Maeda K, Kusuhara H, Suhara T, Sugiyama Y: Possible Role of Organic Cation Transporters in the Distribution of [(11)C]Sulpiride, a Dopamine D2 Receptor Antagonist. J Pharm Sci. 2017 Sep;106(9):2558-2565. doi: 10.1016/j.xphs.2017.05.006. Epub 2017 May 10. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Toxin transporter activity
- Specific Function
- Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
- Gene Name
- SLC22A3
- Uniprot ID
- O75751
- Uniprot Name
- Solute carrier family 22 member 3
- Molecular Weight
- 61279.485 Da
References
- Bai M, Ma Z, Sun D, Zheng C, Weng Y, Yang X, Jiang T, Jiang H: Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884. doi: 10.1007/s00204-017-2008-8. Epub 2017 Jun 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Bai M, Ma Z, Sun D, Zheng C, Weng Y, Yang X, Jiang T, Jiang H: Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884. doi: 10.1007/s00204-017-2008-8. Epub 2017 Jun 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
- Gene Name
- ABCG2
- Uniprot ID
- Q9UNQ0
- Uniprot Name
- ATP-binding cassette sub-family G member 2
- Molecular Weight
- 72313.47 Da
References
- Bai M, Ma Z, Sun D, Zheng C, Weng Y, Yang X, Jiang T, Jiang H: Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884. doi: 10.1007/s00204-017-2008-8. Epub 2017 Jun 9. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 03, 2023 08:07